Why Angiotensin Receptor Blockers Might be Preferred Over Angiotensin Converting Enzyme Inhibitors in COVID-19 Management?
Author(s): Mina T. Kelleni
A recent meta-analysis has suggested that angiotensin-converting enzyme inhibitors might possess more benefit over angiotensin receptor blockers regarding the likelihood of COVID-19 infection and non-COVID pneumonia induced mortality. We present a clinical and pharmacological COVID-19 contradictory point of view, and we also recommend extreme caution when clinical recommendations are considered.